What is HC Wainwright’s Estimate for XBIO Q1 Earnings?

Xenetic Biosciences Inc (NASDAQ:XBIO) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Xenetic Biosciences in a research report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.72) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Xenetic Biosciences Stock Down 0.9 %

Shares of XBIO stock opened at $3.37 on Friday. The business has a 50-day moving average price of $3.98 and a two-hundred day moving average price of $3.99. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.20. The firm has a market cap of $5.20 million, a P/E ratio of -1.27 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.48). Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The firm had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.18 million.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC increased its stake in Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,550 shares of the company’s stock after acquiring an additional 9,700 shares during the period. Renaissance Technologies LLC owned about 1.66% of Xenetic Biosciences worth $102,000 as of its most recent SEC filing. 15.12% of the stock is currently owned by institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.